INFLUENZA VACCINE DEVELOPMENT AND USE
INFLUENZA VACCINE DEVELOPMENT AND USE
批准号:
3811253
负责人:
R A LEVANDOWSKI
金额:
$0.0万
依托单位:
--
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
中文摘要
在1989-1990年流感病毒疫苗中,改变了B组分
英文摘要
For the 1989-1990 influenza virus vaccine the B component was changed
because a new strain, B/Yamagata/16/88, appeared in Southeast Asia. Ferrets
infected with B/Yamagata and sheep immunized with B/Yamagata vaccine
developed hemagglutination inhibition (HI) antibody responses that were not
cross-reactive with other influenza B strains including the predominant
strain, B/Victoria/2/87. However, data from healthy adults indicated that a
broadly reactive HI antibody response could be expected against earlier
influenza B virus strains. In order to determine if the antibody response
in children was similarly broadly crossreactive, sera were collected from
high-risk children who received the commercial trivalent influenza virus
vaccine (which included influenza B/Yamagata/16/88). Sera were tested by
hemagglutination inhibition and neutralization for antibodies against
B/Yamagata/16/88 and B/Victoria/2/87. Two groups of children were
immunized: those with a history of previous influenza virus vaccination and
those with no history of prior vaccination for influenza. The latter group
was younger (mean age 20 months) than the previously immunized group (mean
age 29 months). Seven of the 12 previously immunized children had
preexisting antibody against influenza B viruses. Reciprocal geometric mean
antibody titers (GMT) for these children increased from approximately 8 to
128 for B/Yamagata and from 16 to 128 for B/Victoria. Three of the 11
children not previously immunized had detectable antibody against influenza
B viruses. Excluding those three, the children not previously immunized had
increases in GMT from <8 to 128 for B/Yamagata but no change in titer for
B/Victoria (pre and post GMT <8). There was an extremely good correlation
between HI with detergent disrupted virus and neutralizing antibody titer.
For all sera the data suggest that immunologically primed but not unprimed
children develop a cross reactive antibody response after immunization with
an influenza B virus.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
DEVELOPMENT, STANDARDIZATION AND USE OF INFLUENZA VIRUS VACCINES
-
批准号:3748167
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:R A LEVANDOWSKI
-
依托单位:--
INFLUENZA VACCINE DEVELOPMENT AND USE
-
批准号:3804805
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:R A LEVANDOWSKI
-
依托单位:--
INFLUENZA REASSORTANT VIRUS--BIOLOGY AND GENETICS
-
批准号:3804809
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:R A LEVANDOWSKI
-
依托单位:--
CELLULAR AND HUMORAL IMMUNE RESPONSES TO RHINOVIRUSES
-
批准号:3811252
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:R A LEVANDOWSKI
-
依托单位:--
INFLUENZA VACCINE DEVELOPMENT AND USE
-
批准号:3792535
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:R A LEVANDOWSKI
-
依托单位:--
CELLULAR AND HUMORAL IMMUNE RESPONSES TO RHINOVIRUSES
-
批准号:3792534
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:R A LEVANDOWSKI
-
依托单位:--
IMMUNOLOGY AND BIOLOGY OF RHINOVIRUSES
-
批准号:3770335
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:R A LEVANDOWSKI
-
依托单位:--
DEVELOPMENT, STANDARDIZATION AND USE OF INFLUENZA VIRUS VACCINES
-
批准号:5200730
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:R A LEVANDOWSKI
-
依托单位:--
DEVELOPMENT, STANDARDIZATION AND USE OF INFLUENZA VIRUS VACCINES
-
批准号:3770336
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:R A LEVANDOWSKI
-
依托单位:--
CELLULAR AND HUMORAL IMMUNE RESPONSES TO RHINOVIRUSES
-
批准号:3804804
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:R A LEVANDOWSKI
-
依托单位:--
INFLUENZA REASSORTANT VIRUS--BIOLOGY AND GENETICS
-
批准号:3792539
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:R A LEVANDOWSKI
-
依托单位:--
海外基金